Diabetes is a chronic condition that requires continuous management, often relying on medical devices such as insulin pumps, continuous glucose monitors (CGMs), and automated insulin delivery systems. These devices are not luxuries—they are critical tools that can prevent life-threatening complications. Yet many diabetics face persistent roadblocks when insurance companies or healthcare providers deny coverage or access to these essential items. When a denial occurs, understanding the legal landscape can empower patients to fight back effectively.

Federal and state laws provide multiple layers of protection. The most prominent include the Americans with Disabilities Act (ADA), which prohibits discrimination based on disability, and the Affordable Care Act (ACA), which mandates coverage for essential health benefits. Additionally, the Employee Retirement Income Security Act (ERISA) governs employer-sponsored insurance plans and offers specific remedies for wrongful denials. These statutes form the backbone of legal recourse for diabetics seeking necessary medical devices.

Americans with Disabilities Act (ADA)

The ADA, enacted in 1990, protects individuals with disabilities from discrimination in public accommodations—including healthcare facilities and insurance practices. Diabetes is considered a disability under the ADA because it substantially limits major life activities such as endocrine function and self-care. This classification means that insurers and providers cannot arbitrarily deny access to medically necessary devices solely because of the diabetic’s condition. Courts have repeatedly held that requiring the use of an insulin pump or CGM does not create an undue burden. If a denial is based on discriminatory intent or practices, a lawsuit under Title III of the ADA may be appropriate. For example, in U.S. v. Holy Family Hospital, the court found that denial of necessary diabetes supplies constituted discrimination under the ADA. Similar rulings have reinforced that plan provisions singling out diabetic devices for unfavorable treatment can be challenged.

Affordable Care Act (ACA) Protections

The ACA requires individual and small-group health insurance plans to cover a set of essential health benefits. The Department of Health and Human Services (HHS) has clarified that durable medical equipment—including insulin pumps and CGMs when deemed medically necessary—falls within this category. Many large employer plans also voluntarily cover these devices. Under the ACA, preventive care, including diabetes management tools, cannot have cost-sharing that makes them inaccessible. Denials based on plan exclusions that contradict essential health benefit rules may be challenged through internal appeals followed by external review. If an insurer still refuses, patients can file a complaint with the Center for Medicare and Medicaid Services (CMS) or state regulators. Additionally, the ACA's independent external review process is binding on the insurer and often succeeds when internal appeals fail. Since 2016, CMS data shows external review overturns denials in over 40% of cases involving durable medical equipment.

ERISA: The Employer Plan Safety Net

For the majority of working-age diabetics who receive insurance through employers, ERISA governs how their plans operate. ERISA allows plan participants to sue for benefits if denials are improper, and it also requires that plan administrators follow the plan's terms. Importantly, ERISA claims come with a "reasonable opportunity" for a fair review. If the denial letter fails to explain the specific medical or coverage reasons, or if the insurer applies overly strict criteria, the participant can file a lawsuit under Section 502(a)(1)(B) of ERISA. Additionally, if breaches of fiduciary duty occur—such as when an insurer profits from delaying or denying coverage—the patient may have further recourse. Courts have held that plan administrators must consider all evidence, including medical guidelines from organizations like the American Diabetes Association. A 2022 decision in Davis v. Cigna ordered the insurer to cover an insulin pump after the internal appeal ignored the patient’s hypoglycemia unawareness.

The Role of State Laws and Mandates

Many states have enacted additional protection beyond federal law. As of 2024, over 20 states require health plans to cover diabetes self-management education, and several mandate coverage for CGMs without step therapy. For example, California’s Health and Safety Code explicitly includes insulin pumps and continuous glucose monitors as covered durable medical equipment. Some states also have “any willing provider” laws that prevent plans from denying coverage solely because a device is prescribed by an out-of-network endocrinologist. When building a case, it is critical to review state insurance mandates alongside federal protections. State insurance department complaints can expedite resolution, and some states award attorney’s fees to patients who win appeals.

Common Reasons for Denial and How to Counter Them

Denial notices often cite one of several standard justifications. Knowing these can help patients anticipate arguments and prepare robust counter-documentation. Below are the four most frequent reasons, along with expanded counter-strategies.

  • “Not medically necessary.” This is the most frequent reason. The plan may argue that the patient can manage with multiple daily injections (MDI) rather than a pump, or that finger-stick tests suffice instead of a CGM. Counter: Request a letter from your endocrinologist detailing the medical necessity—citing HbA1c trends, hypoglycemia unawareness, or variability that MDI cannot address. Peer-reviewed studies consistently show that pump therapy reduces complications and improves quality of life. Provide these as evidence. Also, ensure the letter uses language from the plan’s own medical necessity definition, often found in the plan document.
  • “Lack of prior authorization or step therapy.” Many plans require prior authorization or a trial of less expensive therapies before approving a device. Counter: If your provider inadvertently skipped prior authorization, work with their office to correct it. If step therapy applies, document that you have tried and failed with MDI or other treatments. Some state laws have “step therapy override” provisions for chronic conditions like diabetes. For example, 24 states now allow doctors to bypass step therapy for diabetes when it could cause harm. Include a sworn statement from your physician about the failure of alternative treatments.
  • “Plan exclusion for durable medical equipment.” Some policies explicitly exclude certain devices. Counter: Check if the exclusion violates state or federal law. For example, the ACA’s essential health benefits requirement overrides many plan exclusions. Additionally, if the plan is self-funded (often the case with large employers), ERISA may still require that the exclusion does not arbitrarily discriminate. Insurers sometimes use ambiguous wording to deny devices that are clearly medically necessary. A careful reading of the exclusion alongside the device’s FDA indications can reveal that the device actually falls under a covered category (e.g., “therapeutic devices” rather than “convenience items”).
  • “Out-of-network provider.” If your device is prescribed by an out-of-network endocrinologist or supplied by an out-of-network vendor, the plan may deny. Counter: Request a “continuity of care” exception or a single-case agreement. Many plans make exceptions when the device is not available in-network. Document that the in-network options do not provide the same level of technology or expertise. For instance, if the only in-network endocrinologist has limited experience with automated insulin delivery systems, obtain a statement from a qualified specialist explaining why the device must be obtained through an out-of-network provider. Some states require plans to allow single-case agreements when there is no in-network provider with sufficient expertise.

The Appeals Process: A Step-by-Step Guide

When a denial arrives, time is critical. Most plans have strict deadlines for internal appeals—often 60 to 180 days. Follow these steps methodically to maximize your chances of success.

  1. Read the denial letter thoroughly. Note the precise reason and the policy provisions cited. Highlight any vague language. Also note the deadline for filing an appeal—missing it can forfeit your rights.
  2. Contact your provider. Ask your doctor’s office to submit a peer-to-peer review with the insurance company’s medical director. This informal call can sometimes reverse a denial instantly, especially when the clinical need is compelling. Prepare a brief summary for your physician to use during the call.
  3. File an internal appeal. Prepare a written appeal letter that directly rebuts each reason for denial. Attach supporting medical records, lab results, and letters of support. Include a detailed history of your diabetes management and why the device is essential. Use bullet points to highlight key facts. Many experts recommend including a chronology of care that shows the progressive worsening of diabetes management without the device.
  4. Request an external review. If the internal appeal fails, you have the right to an independent external review in all states (under the ACA). The external reviewer is not affiliated with the insurer and can overturn the denial. This step is free and binding on the insurer. The external reviewer will evaluate whether the denial was correct based on medical evidence and plan terms. Studies show that external reviews overturn denials about 40% of the time for durable medical equipment.
  5. Document everything. Keep copies of all correspondence, phone logs (including names and dates), and medical records. This trail is vital for any subsequent legal action. Use a dedicated folder or binder. Also save electronic copies of claim documents and benefit summaries.

Many states also have consumer assistance programs that help with appeals. The federal Health Insurance Marketplace provides a complaint process for ACA-compliant plans. Additionally, the Patient Advocate Foundation offers case management services that can guide you through the appeals maze.

Expanding Your Appeal: The Art of the Medical Necessity Letter

The most powerful tool in an appeal is a well-crafted letter of medical necessity. It should include: the patient’s diagnosis and disease severity, specific clinical markers (e.g., HbA1c >8% despite optimized injections, recurrent severe hypoglycemia), the specific device and why it is the standard of care, evidence of failure of alternative treatments, and peer-reviewed literature supporting device use. If the device has an FDA indication for diabetes management, cite that. Physicians should also reference how denial could lead to increased emergency room visits, hospitalizations, or long-term complications. Such letters should be dated, signed, and on official letterhead. Consider including a statement from a diabetes educator or nurse practitioner who has firsthand experience with your daily management challenges.

If all administrative remedies are exhausted and the denial stands, taking legal action may be the only way to secure the device. The decision to sue should not be taken lightly, but for a device that is medically vital, it is a legitimate option. Legal action can also set a precedent that benefits other patients with the same insurer.

Types of Lawsuits

  • ERISA lawsuit (Section 502(a)(1)(B)): This is the most common route for employer-sponsored plans. The court reviews the administrative record (the denial and appeal documents) de novo or under an arbitrary-and-capricious standard. If the court finds the denial unreasonable, it can order the plan to pay for the device and, in some cases, award attorney’s fees. Under ERISA, you cannot seek compensatory damages, but you can get the device covered and future care unchanged. Rapid-filing injunctions are also possible in urgent cases.
  • ADA discrimination lawsuit: If the denial is part of a pattern of discrimination, or if the insurance plan’s terms treat diabetics differently without a valid reason, a Title III lawsuit may be filed. Remedies include injunctive relief and damages. For example, if the plan covers other chronic conditions’ devices but explicitly excludes CGMs, that may be a basis for an ADA claim. Damages can include emotional distress in some circuits.
  • State contract law breach: For plans not governed by ERISA (like those purchased by individuals outside the marketplace), a breach of contract claim may be appropriate. State law often allows broader damages, including consequential damages for harm caused by the denial. For example, if denial leads to a diabetic ketoacidosis hospitalization, the patient may recover medical costs and lost wages.

Not all attorneys handle health insurance denial cases. Look for those specializing in ERISA litigation, disability rights, or healthcare law. Organizations such as the National Diabetes Advocacy Foundation and Kronenberger Rosenfeld (link: ERISA Lawyers) can provide referrals. Legal aid clinics may assist low-income patients. When interviewing a lawyer, ask about their experience with diabetes device cases, their fee structure (many work on contingency), and whether they have tried cases against specific insurers. Also, check state bar association directories for certified specialists in health law.

Resources and Advocacy Support

Patients should never feel alone in the fight. Several nonprofit and government organizations offer free guidance and advocacy. The following are trusted resources:

  • American Diabetes Association (ADA): Their website provides sample appeal letters and toolkits for navigating denials. Visit diabetes.org for model letters and state-specific mandate information.
  • Beyond Type 1: Offers a Facebook group where patients share experiences and tips for insurance battles. They also publish guides on prior authorization and step therapy overrides.
  • State Insurance Departments: Every state has a consumer hotline for insurance complaints. They can intervene on your behalf. File complaints online; many departments respond within 30 days.
  • Patient Advocate Foundation: Provides case management services for patients facing coverage denials, including direct phone support and help drafting appeal letters.
  • Centers for Medicare & Medicaid Services (CMS): For Medicare or ACA plans, you can file a complaint at cms.gov. Medicare provides a separate expedited appeals process for life-sustaining devices.
  • JDRF: Advocates for type 1 diabetes research and coverage. They have a resource page for insurance appeals specific to continuous glucose monitors.

Social media and diabetes-focused online communities can also alert patients to pattern denials from specific insurers. Collective advocacy has led to policy changes in the past, such as when major insurers reversed across-the-board denials of Dexcom CGM systems. Join groups like #DiabetesAccess on Twitter or the "Diabetes Insurance Advocacy" Facebook group to share stories and strategies.

Proactive Steps to Protect Your Rights

Being denied a life-improving or life-saving medical device because of insurance red tape is unjust, but the law provides multiple avenues for recourse. Diabetics should not accept a denial as final. By understanding the legal framework under the ADA, ACA, and ERISA, carefully documenting the clinical need, and exhaustively pursuing appeals—with legal action as a backup—patients can often prevail. The key is to act quickly, gather strong medical evidence, and leverage the resources of advocacy groups. In a healthcare system that sometimes prioritizes cost over care, knowing your legal rights is the most powerful tool in your diabetes management arsenal. Every patient who fights back not only helps themselves but also helps set a precedent that makes it harder for insurers to deny necessary devices to others. Start building your case today: download sample appeal letters, contact your state insurance department, and consult with an attorney experienced in health coverage denials. Your health—and your future—depends on it.